Oncology News

LAS VEGAS – In this video exclusive, Nancy S. Reau, MD, FAASLD, AGAF, discussed the Liver Health Annual Trends Report, which was launched during a panel discussion hosted by Salix Pharmaceuticals at the ACG Annual Scientific Meeting.

LAS VEGAS – In this video exclusive, Donna Cryer, JD, founder, president and CEO Global Liver Institute, spoke on the launch of the Liver Health Annual Trends Report and its possible impact for patients with chronic liver disease.

LAS VEGAS – In this video exclusive from the ACG Scientific Annual Meeting, Amit Singal, MD, from UT Southwestern Medical Center, discussed best practices for the screening, surveillance, and treatment of hepatocellular carcinoma.

The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

Pembrolizumab prolonged OS compared with placebo for certain patients with advanced hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

Recently the European Association for the Study of the Liver updated its clinical practice guidelines for management of hepatocellular carcinoma.

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib.

The combination of cabozantinib and atezolizumab prolonged PFS compared with sorafenib among patients with previously untreated advanced hepatocellular carcinoma, according to topline data released by one of the agent’s manufacturers.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Transforming growth factor beta mutation biomarkers may help identify patients at high risk for cancer of the liver, pancreas and gastrointestinal system, according to data published in Gastroenterology.